Several studies, including NeoPalAna24, neoMONARCH25, and FELINE26, supported the efficacy of different CDK4/6 inhibitors combined with ET for achieving CCCA in various subsets of breast cancer patients. This evidence concerns the gene CDK4 and breast cancer.